Kalbe Genexine Biologics Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2016

Location

Jakarta Indonesia

Primary Industry

Biotechnology

About

Based in Jakarta, Indonesia, and established in 2016, Kalbe Genexine Biologics, a life sciences arm of PT. Kalbe Farma Tbk., operates as a provider of biological and biosimilar drugs in Southeast Asia. The company was a joint venture of PT. Kalbe Farma Tbk. and Genexine, a South Korea-based clinical-stage biotechnology company. The company focuses on pre-clinical and clinical development, CMC process development, regulatory and quality compliance, and has two licensed clinical-stage biological drugs PD-1 for various oncology indications, and a third-generation Erythropoietin for CKD-induced anemia. In 2020, Kalbe Genexine Biologics generated a sales turnover of USD 12 million and USD 41 million of total assets value. The company plans to expand its portfolio with the support of Genexine and General Atlantic.

Current Investors

General Atlantic

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biotechnology

Website

www.kalbe.co.id

Company Stage

Mature - Growth Capital

Total Amount Raised

Subscriber access only

Financials

Fiscal Year Ended
Revenue (USD)
% Revenue Growth (YoY)
Operating Income (USD)
Operating Margin
EBITDA (USD)
% EBITDA Margin
NET Income (USD)
% Net Margin

31 Dec 2011

10,911,860,141,523

1,903,498,281,439

17.4%

1,957,281,716,571

17.9%

1,522,956,820,292

14%

31 Dec 2012

13,636,405,178,957

25%

2,251,061,699,120

16.5%

2,302,758,172,516

16.9%

1,775,098,847,932

13%

31 Dec 2013

16,002,131,057,048

17.3%

2,550,739,699,214

15.9%

2,609,319,718,473

16.3%

1,970,452,449,686

12.3%

31 Dec 2014

17,368,532,547,558

8.5%

2,752,341,947,710

15.8%

2,823,888,233,159

16.3%

2,121,090,581,630

12.2%

31 Dec 2015

17,887,464,223,321

2,643,465,735,736

14.8%

2,727,745,465,531

15.2%

2,057,694,281,873

11.5%

31 Dec 2016

19,374,230,957,505

8.3%

2,987,003,409,934

15.4%

3,085,727,939,651

15.9%

2,350,884,933,551

12.1%

31 Dec 2017

20,182,120,166,616

4.2%

3,142,664,059,158

15.6%

3,293,174,095,446

16.3%

2,453,251,410,604

12.2%

31 Dec 2018

21,074,306,186,027

4.4%

3,210,351,360,738

15.2%

3,356,040,389,042

15.9%

2,497,261,964,757

11.8%

31 Dec 2019

22,633,476,361,038

7.4%

3,305,099,077,777

14.6%

3,457,263,807,971

15.3%

2,537,601,823,645

11.2%

31 Dec 2020

31 Dec 2021

31 Dec 2022

Unlock the recent years of financials and more for Kalbe Genexine Biologics.

Request a demo to see more.

Deals

Deals Type
Growth

Deal Status	Target (s)	Deal Date	Investor(s)	Seller(s)	Deal size (Mn)	Enterprise value (Mn)	Post-money valuation (Mn)	EBITDA multiple (x)	Revenue multiple (x)	Lead partner (s)
Completed	Kalbe Genexine Biologics	27 Jan 2021

Displaying 1-1 of 1

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.